Globale Marktgröße, Prognose und Trend Highlights über 2024-2036
Acute Myeloid Leukemia market size was valued at USD 2 trillion in 2023 and is set to reach USD 7 trillion by the end of 2036, registering over 10% CAGR during the forecast period of 2024-2036. In 2024, the Acute Myeloid Leukemia industry size is estimated to be USD 3 billion.
The number of acute myeloid leukemia patients is increasing due to the aging population around the world. Like many other malignancies, acute myeloid leukemia (AML) is a hematologic neoplasm that typically affects older people, with a median age of 67 years.
According to the World Health Organization (WHO), the number of people aged 60 and over worldwide will double by 2050 (to 2.1 billion).
Akute Myeloid Leukemia Sektor: Wachstumstreiber und Herausforderungen
growth drivers
- Integrating personalized medicine – In acute myeloid leukemia, precision medicine is used through molecular profiling to identify specific genetic mutations and unique biomarkers for each patient.< br />
To achieve a more personalized and precise approach to AML management, information guides the selection of targeted therapies and tailored treatment plans, optimizing the effectiveness of interventions and minimizing side effects.
According to a study conducted four years ago by the Leukemia & Lymphoma Society (LLS), patients with acute myeloid leukemia (AML) who received precision medicine had better survival outcomes and a much lower early mortality rate, faring far better than individuals who started therapy early in life. - Development of advanced treatment options – Several research studies are being conducted to demonstrate the effectiveness of the drugs, leading to the development of advanced treatment options and a better understanding of acute myeloid leukemia (AML).
For example, according to the United States National Library of Medicine, the research titled “Daunorubicin or idarubicin with cytarabine plus quizartinib vs. physician's choice in newly acquired FLT3-ITD+ AML (Q-SOC)” is currently in Phase III clinical trials.
challenges
- Lack of awareness and education – Despite efforts to raise awareness, there may still be gaps in knowledge and understanding among healthcare professionals, patients and the public about AML. Delayed diagnosis, inadequate treatment decisions and poor patient outcomes may be associated with a lack of awareness.
- Resistance to conventional therapies – Due to a high percentage of treatment failure caused by an increasing prevalence of drug resistance causing disease relapse, AML remains the leading cause of leukemia-related mortality.
Relapsed and refractory AML is associated with a poor prognosis due to inadequate response to conventional antileukemic therapy, which relies on proteins and enzymes with altered function, pathway dysregulation, mutations in cell cycle control genes, epigenetic modifiers and microRNA.
Acute Myeloid Leukemia Markt: Schlüsselinsights
|
base year |
2023 |
|
forecast year |
2024-2036 |
|
CAGR |
10% |
|
base year market size |
2 billion US dollars |
|
forecast market size for the year |
7 billion US dollars |
|
Regional scope |
|
Akute Myeloid Leukemia Segment
Treatment type [chemotherapy (cytarabine, anthracycline drugs, alkylating agents, antimetabolites, tyrosine kinase inhibitors, hormone therapy), targeted therapy, immunotherapy, hormone therapy]
The chemotherapy segment is estimated to capture over 62% market share in acute myeloid leukemia by 2036. Chemotherapy is significantly used for the solidification treatment of acute myeloid leukemia. Due to its effectiveness in curing AML, cytarabine is widely used during chemotherapy.
According to cancer organizations, cytarabine, a type of chemotherapy drug, is more effective in treating acute myeloid leukemia and is therefore used so widely.
The growth of this market is also expected to be driven by an increase in U.S. Food and Drug Administration approvals for cytarabine for the treatment of acute myelodysplastic syndrome.
For example, in March 2021, Jazz Pharmaceuticals plc announced that it had received approval from the U.S. Food and Drug Administration (FDA) to add revised labeling for Vyxeos (daunorubicin and cytarabine) to include a new indication for the treatment of children one year of age and older with newly diagnosed treatment-emergent acute myeloid leukemia or AML with myelodysplasia-related changes, to advance cancer research and focus it on those individuals who can most benefit.
End users (hospitals, home care, specialty centers)
The hospital segment in the acute myeloid leukemia market is expected to grow at over 10% CAGR between 2024 and 2036. The growth is attributed to the growing healthcare industry. Several countries across the world are investing in the development of healthcare infrastructure, which is leading to the improvement in cancer treatment and diagnostic capabilities through earlier detection and treatment of acute myeloid leukemia.
More and more hospitals around the world are being equipped with advanced facilities to provide integrated care for AML patients. In addition, hospitals are providing patients with preventive and treatment options under one roof.
For example, the healthcare sector in India is expected to generate more than $600 billion by 2026.
disease type (myeloblastic, promyelocytic, myelomonocytic)
The myeloblastic segment is expected to dominate over 40% market share in acute myeloid leukemia by 2036. This growth of the segment is expected to be promoted by the growing pediatric population. Acute myeloblastic leukemia, the second most common type of leukemia in children, is a malignant disease in which the bone marrow produces a tremendous amount of abnormal blood cells and has the poorestb_regional_synopsys_descriptione prognosis of all childhood cancers.
It is estimated that more than 20% of the people on the planet are under 15 years old.
Our in-depth analysis of the market covers the following segments:
|
disease type |
|
|
treatment type |
|
|
route of administration |
|
|
end user |
|
|
distribution channel |
|
|
regime |
|
Möchten Sie diesen Forschungsbericht an Ihre Anforderungen anpassen? Unser Forschungsteam wird die von Ihnen benötigten Informationen bereitstellen, um Ihnen zu helfen, effektive Geschäftsentscheidungen zu treffen.
Diesen Bericht anpassenAcute Myeloid Leukemia Industry - Regionale Synthese
North American market forecasts
North America is estimated to account for over 40% revenue share in the acute myeloid leukemia market by the end of 2036. The growth of this market in the region is driven by the growing research and development and product launches. This has led to the discovery of more effective therapies in the field of acute myeloid leukemia.
In addition, the increasing incidence of acute myeloid leukemia in the United States is expected to drive market expansion. For example, in 2022, there were 60,650 new cases of leukemia cancer in the United States, with 24,000 of these cases expected to result in death.
Canada has gradually increased AML incidence rates, with an estimated average of 30.61 cases per million people per year.
APAC market statistics
The Asia Pacific acute myeloid leukemia market is expected to grow significantly during 2024–2036. Due to population growth, the prevalence of AML is increasing in the region. As a result, the acceptance of novel treatments and therapies is increasing, resulting in more people receiving timely therapy.
According to UNFPA, about 4.3 billion people, or 60% of the world's population, live in the Asia-Pacific region.
China is home to one in five children worldwide suffering from acute lymphoblastic leukemia, and more than 55% of the 75.3 thousand new cases of leukemia in China each year are AML patients.
The majority of adult leukemia cases in Korea are caused by acute myeloid leukemia (AML), a representative malignant blood disease that is a significant health concern nationwide.
Recently, significant progress has been made in identifying and treating AML in Japan , leading to a need for novel and more effective AML treatments. AML and other diseases such as multiple myeloma are major focuses of the Japanese government, which continually seeks to improve access to current medicines while encouraging research into novel AML treatments.
Unternehmen dominieren die Akute Myeloid Leukemia Landschaft
- Pfizer Inc.
- company overview
- business strategy
- Important product offers
- financial result
- Key Performance Indicators
- risk analysis
- Current Development
- Regional presence
- SWOT analysis
- Novartis International AG
- Celgene Corporation
- Bristol-Myers Squibb Company
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and company
- GlaxoSmithKline plc
- Sanofi-Aventis (Genzyme Corporation)
- Sunsis Pharma Inc.
The acute myeloid leukemia market consists of several key players who are launching various strategic initiatives to expand their market position in the acute myeloid leukemia industry.
In the News
- Novartis International AG announced that it has successfully acquired Cadent Therapeutics, a clinical-stage biotechnology company developing drugs for neurological and psychiatric disorders. The aim of this acquisition was to expand the range of drugs provided by Novartis for cancer and gene therapy, in particular AML therapies.
- Bristol-Myers Squibb announced that its product, Onureg, has been approved by the FDA for maintenance therapy of AML in patients who have been completely cured after aggressive chemotherapy. This drug is the first and only oral medicine to be approved by the FDA for this use.
Autorenangaben: Radhika Pawar
- Report ID: 2894
- Published Date: May 24, 2024
- Report Format: PDF, PPT
